# OnCo record paper-mu-sox2-lineage-plasticity-science-2017 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-mu-sox2-lineage-plasticity-science-2017" ;
  schema:name "SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer"@en ;
  schema:alternateName "Mu 2017"@en, "SOX2 lineage plasticity prostate"@en, "enzalutamide resistance by lineage switching"@en ;
  schema:description "Some prostate cancers escape hormone drugs not by changing the receptor but by becoming a different kind of cell that does not need it. This paper showed how: losing two tumour suppressors lets the cell switch on SOX2 and change identity, and restoring them reverses it."@en ;
  schema:url <https://onco.cc/key-papers/paper-mu-sox2-lineage-plasticity-science-2017/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1126/science.aah4307>, <https://pubmed.ncbi.nlm.nih.gov/28059768/> ;
  onco:tag "prostate-evidence" ;
  schema:sameAs <https://doi.org/10.1126/science.aah4307> ;
  schema:datePublished "2017"^^xsd:gYear ;
  schema:author "Mu P, Zhang Z, Benelli M, et al." ;
  onco:related <https://onco.cc/key-papers/paper-ku-rb1-trp53-lineage-plasticity-science-2017/>, <https://onco.cc/key-papers/paper-beltran-nepc-divergent-evolution-nat-med-2016/>, <https://onco.cc/key-papers/paper-aggarwal-t-sccpc-jco-2018/>, <https://onco.cc/key-papers/paper-rubin-mol-cell/>, <https://onco.cc/ideas/idea-bio1-cfrna-plasticity-tracking/>, <https://onco.cc/roadmaps/prostate-roadmap/> ;
  onco:cancers <https://onco.cc/cancers/prostate/>, <https://onco.cc/cancers/prostate-mcrpc/>, <https://onco.cc/cancers/prostate-nepc/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/>, <https://onco.cc/fronts/epigenetics/> ;
  onco:targets <https://onco.cc/targets/tp53/>, <https://onco.cc/targets/rb1/>, <https://onco.cc/targets/androgen-receptor/>, <https://onco.cc/targets/sox2/> ;
  onco:institutions <https://onco.cc/institutions/mskcc/> ;
  onco:pathways <https://onco.cc/pathways/lineage-plasticity-neuroendocrine/>, <https://onco.cc/pathways/epigenetic-reprogramming/>, <https://onco.cc/pathways/ar-signaling/>, <https://onco.cc/pathways/cancer-stem-cells-plasticity/> ;
  onco:terms <https://onco.cc/terms/castration-resistance/>, <https://onco.cc/terms/neuroendocrine-differentiation/>, <https://onco.cc/terms/histologic-transformation/>, <https://onco.cc/terms/resistance/> ;
  onco:people <https://onco.cc/people/charles-sawyers/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-resistance/>, <https://onco.cc/bottlenecks/b-undruggable-targets/>, <https://onco.cc/bottlenecks/b-tumor-heterogeneity/> ;
  onco:journals <https://onco.cc/journals/science/> .